Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications

• Published in: Expert opinion on biological therapy Vol. 20; no. 9; pp. 1025 - 1031
• Main Authors: Loganathan, Subramanian, Athalye, Sandeep N., Joshi, Shashank R.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01.09.2020
• Subjects: Anti-CD6; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Antigens, CD - immunology; Antigens, Differentiation, T-Lymphocyte - immunology; Betacoronavirus; Cell Differentiation - drug effects; Cell Differentiation - physiology; Cell Proliferation - drug effects; Cell Proliferation - physiology; Coronavirus Infections - drug therapy; Coronavirus Infections - immunology; COVID-19; cytokine storm; Cytokines - antagonists & inhibitors; Cytokines - immunology; Humans; inflammatory; Itolizumab; Lymphocyte Activation - drug effects; Lymphocyte Activation - physiology; monoclonal antibodies; Pandemics; plaque psoriasis; Pneumonia, Viral - drug therapy; Pneumonia, Viral - immunology; SARS-CoV-2; T-Lymphocytes - drug effects; T-Lymphocytes - immunology; Treatment Outcome; COVID-19; Anti-CD6; Itolizumab; cytokine storm; inflammatory; plaque psoriasis; monoclonal antibodies

The globally rampant SARS CoV-2 pandemic requires novel medical strategies to control the severity of disease and death due to complications. Of the 15-20% patients that develop pulmonary symptoms, a sub-set develops an acute respiratory distress syndrome (ARDS) rapidly progressing into a critical c...